




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## UPDATE IN INTENSIVE CARE MEDICINE: CRITICAL PATIENT WITH SERIOUS INFECTION

# Role of viral infections in immunosuppressed patients

M. Salavert,<sup>a</sup> R. Granada,<sup>b</sup> A. Díaz,<sup>c</sup> R. Zaragoza<sup>d,\*</sup>

<sup>a</sup>Unidad de Enfermedades Infecciosas, Hospital Universitario y Politécnico La Fe, Valencia, Spain

<sup>b</sup>Servicio de Medicina Intensiva, Hospital Universitario de Bellvitge, l'Hospitalet de Llobregat, Barcelona, Spain

<sup>c</sup>Servicio de Medicina Intensiva, Hospital Universitario Virgen del Rocío, Sevilla, Spain

<sup>d</sup>Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, Spain

Received 29 November 2010; accepted 11 December 2010

### KEYWORDS

Viral infection;  
Cytomegalovirus;  
Respiratory viruses;  
Immunodepressed  
patients;  
Transplant

**Abstract** Being a solid organ and hematopoietic stem cell transplant recipient as well as receiving chemotherapy for a malignant hematological disease clearly predispose the subject to a variety of viral infections, both common and opportunistic diseases. The patient may have acquired these infections from the community as well as from the donor organ (donor-derived infections) and/or from reactivation of an endogenous latent virus. Herpes viruses and especially the cytomegalovirus and Epstein-Barr virus are among the most common of the opportunistic viral pathogens affecting these patients, in addition to respiratory viruses. Treatment consists in antiviral drug therapies combined with the reduction in the degree of the induced immunosuppression. A review of the literature has been performed in order to update the epidemiology, pathogenesis, clinical manifestations and therapeutic approach of the viral infections in these immunocompromised patients.

© 2010 Elsevier España, S.L. and SEMICYUC. All rights reserved.

### PALABRAS CLAVE

Infección viral;  
Citomegalovirus;  
Virus respiratorios;  
Pacientes  
inmunodeprimidos;  
Trasplante

### Papel de las infecciones víricas en pacientes inmunodeprimidos

**Resumen** Ser receptor de un trasplante de órgano sólido, así como recibir tratamiento quimioterápico para una enfermedad hematológica maligna, predispone claramente a padecer infecciones virales tanto comunes como oportunistas, de origen tanto comunitario como procedentes del donante de órganos y/o de una reactivación de un virus latente endógeno. Herpes virus y más especialmente citomegalovirus y virus de Epstein-Barr son los que con más frecuencia afectan a estos enfermos, así como los virus respiratorios. El tratamiento consiste en la combinación de reducir la inmunodepresión inducida junto con tratamiento antiviral. Se ha realizado una revisión de la literatura pormenorizada y actualizada de la epidemiología, la patogenia, las manifestaciones clínicas y la aproximación terapéutica de las infecciones virales en estos enfermos.

© 2010 Elsevier España, S.L. y SEMICYUC. Todos los derechos reservados.

\*Corresponding author.

E-mail address: zaragoza raf@gva.es (R. Zaragoza).

## Patients with solid organ transplants and viral infections

### Introduction

In the last two decades, solid organ transplantation (SOT) has become the treatment of choice for many diseases which in the past led to patient death due to the failure of one or more vital organs. In addition to developments in the different surgical and anesthetic techniques, there is no doubt that advances in immunosuppressor treatment have played a key role in allowing such improvements in therapy. Infections are the most frequent complications in transplant recipients,<sup>1</sup> and are the main cause of death during the first year after transplantation. SOT recipients are particularly vulnerable to common or opportunistic viral infections.<sup>2</sup> Such infections may derive from the donor organ (donor-derived infections) or may be community-acquired or correspond to the reactivation of latent endogenous viruses of the patient. Apart from the direct harmful effects of many of these viruses,<sup>3</sup> mention must be made of the immune modulating and inflammatory actions of some of them, which can give rise to very important indirect effects<sup>4</sup> such as acute or chronic graft rejection, or the favoring of other opportunistic infections.

The extensive herpesvirus family, and very particularly cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are among the most frequent opportunistic viral pathogens causing infection in SOT patients.<sup>5-7</sup> These viruses are closely followed in order of frequency and importance by herpes simplex virus (HSV), varicella-zoster virus (VZV) and type 6 human herpes virus (HHV-6), with the infectious syndromes typically produced by them. In the last two decades two new types of herpesvirus have been added<sup>8</sup>: human herpes virus types 7 and type 8 (HHV-7, HHV-8), which cause proliferative or neoplastic diseases in these transplant patients. Other less common types of varied and characteristic processes produced by viral families such as papillomavirus (human papillomavirus [HPV]), polyomavirus (BK virus [BKV] and JC virus [JCV]) and erythrovirus B19 (previously referred to as parvovirus B19).

On the other hand, in certain types of SOT such as liver transplantation, hepatotropic viruses such as hepatitis B virus (HBV) and hepatitis C virus (HCV) are also important, and can condition transplant outcome.

In reference to the community-acquired viruses, practically any of them can cause infections in SOT patients, though in recent times special emphasis<sup>9</sup> has been placed on respiratory viruses such as respiratory syncytial virus (RSV), influenza and parainfluenza viruses, metapneumovirus (MPV) and bocavirus, neurotrophic viruses such as lymphocytic choriomeningitis virus (LCMV), West Nile virus (WNV) and rabies virus, as well as the viruses that cause measles and mumps, coronavirus and rotavirus.

### Modifying factors

Viral infections in SOT patients are conditioned by at least three groups of factors that modify their frequency and time and form of presentation:

- The transplanted organ, the surgical modality and technique used for transplantation, and the immune suppression protocol used.<sup>10</sup>
- The relationship between the serological status<sup>11</sup> of the donor and that of the recipient (D/R status).<sup>12</sup>
- The prophylactic measures adopted to prevent the development of viral disease, universal prophylaxis, selective risk-adapted prophylaxis, prolonged prophylaxis, deferred prophylaxis or anticipatory therapy.<sup>13-15</sup>

### Infection risk periods

Viral infections, in the same way as infections caused by other microorganisms, follow a defined chronological pattern involving well defined periods (Fig. 1)<sup>16</sup>:

- The first period covers the first four weeks after surgery. In this interval the risk of infection is very high, and is fundamentally related to nosocomial bacteria and, to a lesser degree, fungi (*Candida* and *Aspergillus*) - with clinical manifestations similar to those found in other surgical patients. Viral infections are infrequent in this phase.
- The second period extends from the end of the postoperative interval to the sixth month. The risk of infection in this case is lower, and the microorganisms involved tend to be opportunistic organisms - including many of the aforementioned viruses.
- In the third period, starting from the sixth month after transplantation, the risk of infection decreases considerably, and the infections are usually produced by out-hospital microorganisms. During this period, a minority of patients in which the grafted organ does not evolve correctly may suffer infections that are more characteristic of the preceding two periods.

### Clinical manifestations

Both the common and opportunistic viruses are able to produce a broad range of infectious syndromes with very different clinical behaviors in SOT recipients. The disorders may range from scanty expressive or oligosymptomatic clinical conditions, characterized only by fever and detectable viremia, to processes that are extremely serious because of serious structural and functional damage to the grafted organ (more susceptible to infection and greater damage) or to other target organs (due to special tropism shown by some viruses), or because of their disseminated and systemic nature. In this context, mention can be made of simple infection due to CMV with fever and cytomegaloviremia, but also of serious organ-specific disease<sup>17</sup> such as enterocolitis (with hemorrhagic characteristics in some cases), pneumonia (including even a bilateral alveolointerstitial pattern with severe respiratory failure or adult respiratory distress syndrome [ARDS]), hepatitis, retinitis and encephalitis.

Very similar behavior can be shown by other viruses of the herpes family, such as HSV, VZV and HHV-6,<sup>18</sup> causing more or less extensive and characteristic (vesicular or non-vesicular) exanthematic mucocutaneous disease, with the particularity of being able to spread to or affect other organs. Presentations of a particularly serious nature include




Figure 1 Chronology and infection risk periods in SOT patients. CMV: cytomegalovirus, EBV: Epstein-Barr virus, HSV: herpes simplex virus, VZV: varicella-zoster virus, RSV: respiratory syncytial virus, PTLD: post-transplantation lymphoproliferative disease, UTI: urinary tract infection.

hepatitis, pneumonitis, gastrointestinal forms (esophagitis and colitis), and especially the neuro-ophthalmological forms of meningoencephalitis, encephalomyelitis and retinitis. Fortunately, this viral family is susceptible to treatment with specific antiviral agents of established efficacy.<sup>19</sup> In this context, EBV can cause various types of very distinct infectious syndromes (Table 1), though post-transplantation lymphoproliferative disease (PTLD) is of particular importance due to its clinical repercussions and exclusive management characteristics.<sup>20,21</sup>

The polyomaviruses produce a broad range of relevant clinical conditions depending upon their tropism and invasiveness, giving rise to severe demyelination phenomena such as progressive multifocal leukoencephalopathy (PML) in the case of JCV and to a varied number of processes in the case of BKV,<sup>22,23</sup> such as graft interstitial nephropathy (in renal transplants) - with the risk of transplanted organ loss, ureteral stenosis, hemorrhagic cystitis, meningoencephalitis or urothelial carcinoma (Table 2). Erythrovirus B19 shows a strong attraction for hematopoietic precursors, particularly of the red cell line, and can cause serious and refractory aplastic anemia and pancytopenia,<sup>24</sup> as well as induce arthritis, rash and a risk of serious organ disease.

Both *de novo* hepatitis and reactivations, reinfections or recurrences of the disease due to HBV and HCV can cause serious inconveniences for SOT patients and affect the

prognosis and outcome of the transplant, particularly in the case of liver transplant patients. In contrast to HBV recurrence, which is effectively contained by specific immunoglobulins and antiviral agents, no effective prophylaxis against hepatitis C is available, and this disease is almost sure to prove recurrent. The post-transplant evolution depends on prevention of reinfection of the transplanted organ,<sup>25</sup> limited by different host factors<sup>26</sup> and by the toxicity of the antiviral drugs used against HCV - including pegylated interferons.<sup>27</sup> A substantial proportion of HCV infected patients suffer terminal recurrent liver allograft disease, leading to diminished survival of the transplanted organ, an increased need for liver retransplantation, and ultimately a reduction in patient survival.<sup>28</sup> These aspects have gained increased importance following the introduction early in the decade of liver transplantation procedures in patients coinfecting with the human immunodeficiency virus (HIV) and HCV,<sup>29-31</sup> since these individuals exhibit a faster cirrhosis progression rate that leads to an increased frequency of cirrhosis, terminal liver disease and hepatocellular carcinoma.

### Treatment

The treatment of viral infections in SOT patients with effective antiviral drugs must be complemented by a reduction in the grade and intensity of immune suppression

Table 1 Treatment of herpesvirus family infections and their different entities in transplant patients

| Virus  | Treatment of choice   | Alternative options   |
|--|---|---|
| <i>CMV</i>                                       | Ganciclovir (5 mg/kg/12 h, i.v.) or valganciclovir (900 mg/12 h, p.o.) (14 days)  | Foscarnet <sup>a</sup> (60 mg/kg/8 h, i.v., 14-21 days)               |
| Without visceral involvement                     | Ganciclovir (5 mg/kg/12 h, i.v., 14-21 days)  | Cidofovir <sup>b</sup> (induction with 5 mg/kg/weekly, first 2 weeks) |
| With visceral involvement                        | Ganciclovir (5 mg/kg/12 h, i.v., 14-21 days) ± specific or polyvalent immunoglobulin <sup>c</sup>                               |   |
| Pneumonia  |   |   |
| <i>HHV-6</i>                                     | Ganciclovir (5 mg/kg/12 h, i.v.) or valganciclovir (900 mg/12 h, p.o.) (14 days)  | Foscarnet <sup>a</sup> (60 mg/kg/8 h, i.v., 14 days)                  |
| <i>HSV</i>                                       | Aciclovir (200 mg 5 times a day, p.o., 7 days)  | Famciclovir (250 mg/8 h, p.o., 7 days)                                |
| Mild mucocutaneous                               | Aciclovir (5 mg/kg/8 h, i.v., 10-14 days)   | Valaciclovir (1 g/12 h, p.o., 7 days)                                 |
| Severe and visceral mucocutaneous                | Aciclovir (10 mg/kg/8 h, i.v., 21 days)   | Foscarnet <sup>a</sup> (40 mg/kg/8 h)                                 |
| Meningoencephalitis                              |   |   |
| <i>VZV</i>                                       | Aciclovir (800 mg 5 times a day, p.o., 7 days)  | Famciclovir (500 mg/8 h, p.o., 10 days)                               |
| Localized in a dermatome                         | Aciclovir (10 mg/kg/8 h, i.v., 10-14 days)  | Valaciclovir (1 g/8 h, p.o., 7 days)                                  |
| Disseminated zoster or varicella                 |   |   |
| <i>EBV</i>                                       |   |   |
| Non-complicated infectious mononucleosis         | Aciclovir (10 mg/kg/8 h, i.v., 21 days)   |   |
| Benign polymorphic B cell monoclonal hyperplasia | Aciclovir + reduction of immune suppression   |   |
| B cell polyclonal polymorphic lymphoma           | Aciclovir + reduction of immune suppression + anti-CD20 monoclonal antibodies (rituximab)                                       |   |
| B cell monoclonal polymorphic lymphoma           | Reduction of immune suppression + anti-CD20 monoclonal antibodies (rituximab) + chemotherapy and/or radiotherapy and/or surgery |   |

i.v.: intravenous route; p.o.: per os (oral route).

<sup>a</sup>In the case of suspicion or evidence of strains resistant to aciclovir or ganciclovir, foscarnet is the treatment of choice.

<sup>b</sup>In the case of treatment failure with ganciclovir, and when foscarnet causes serious adverse effects, is not well tolerated, or fails to elicit sufficient response. Before each administration, serum creatinine and urine proteins are to be determined, administering cidofovir with probenecid via the oral route, and intravenous saline solution as prehydration measure.

<sup>c</sup>The joint use of ganciclovir and immunoglobulin has been shown to be effective in hematopoietic precursor cell transplantation; most SOT groups extrapolate the results to their patients, though there is no definitive evidence in this respect.

(a key consideration when representing the only effective strategy for the management of viral infections). The prevention of viral infections in SOT patient is of capital importance and can be achieved by implementing different measures such as vaccination programs and certain antiviral strategies, as has been accepted on a consensus basis in the case of *CMV*.<sup>32,33</sup>

## Viral infections in hematological patients

### Introduction

Hematological patients present different types of immune disorders, depending on the hematological disease involved, its evolutive status, and the treatment provided. Such immune problems favor the development of serious

infections that in turn increase patient morbidity-mortality.

In recent years, viral infections have gained importance in this group of patients, which in clinical practice can be classified as oncohematological patients, hematopoietic precursor cell transplant (HPCT) recipients, and blood product recipients. The epidemiology is changing, and the spectrum of severe viral infections is increasing among patients which until a few years ago did not usually suffer such infections. This largely has been a consequence of the use of new drugs with a marked immunosuppressor effect.

There are three types of immune deficiency: neutropenia, cellular immune deficiency and humoral immune deficiency. Each type of immune depression is associated with a certain type of infection; however, different types of immune deficiency tend to coexist in the case of hematological diseases.<sup>34</sup>

Table 2 Emergent viruses in SOT: diagnostic methods, clinical presentations and treatment options

| Virus (seasonality)                     | Diagnosis  | Clinical manifestations  | Treatmenta  |
|---|--|--|---|
| Bocavirus (late autumn, winter)         | PCR  | Fever, rhinorrhea, cough, diarrhea, disseminated infection   | Unknown   |
| Non-SARS CoV strains                    | Culture, PCR   | Upper and lower respiratory tract infections   | -   |
| Erythrovirus B19                        | Serology, PCR, bone marrow biopsy  | Arthralgia/arthritis, anemia, pancytopenia, hepatitis, pneumonitis, myocarditis, glomerulonephritis  | IG i.v.   |
| HHV-6                                   | PCR, <sup>b</sup> culture in viral media, shell-vial culture, histopathology | Fever, hepatitis, pneumonitis, pancreatitis, meningoencephalitis, enteritis, gastritis, rash (short-lasting), pancytopenia, T cell dysfunction, thrombotic microangiopathy | Ganciclovir (variant A), foscarnet, cidofovir                                       |
| LCMV                                    | Serology, PCR, culture   | Fever, diarrhea, abdominal pain, dyspnea, headache, rash, hepatitis, prolonged PT, aseptic meningitis  | Ribavirin (i.v.) <sup>c</sup>   |
| Measles                                 | Serology   | Fever, rash, pneumonitis   | -   |
| Metapneumovirus (end of winter)         | Culture, PCR   | Upper respiratory tract infection, pneumonia, diffuse alveolar hemorrhage  | Ribavirin (i.v.) <sup>c</sup>   |
| Parotiditis (mumps)                     | Serology, PCR  | Mumps, fever   | -   |
| Papillomavirus (HPV)                    | Histopathology, cytology, PCR, EM  | Anogenital papillomas and warts, cervical neoplasms  | Podofilox or podophyllin tincture, imiquimod, interferon-alpha (local application)  |
| Polyomavirus (JCV, BKV)                 | Histopathology, cytology, culture, PCR, EM                                   | CNS demyelination, PML, meningoencephalitis, severe nephritis with renal graft loss, ureteral stenosis, hemorrhagic cystitis, urothelial carcinoma, prostatic neoplasms    | Cidofovir, <sup>d</sup> cytosine arabinoside, <sup>c</sup> leflunomide <sup>c</sup> |
| Rotavirus                               | Stool antigen detection tests, PCR, EM                                       | Diarrhea, gastrointestinal bleeding  | -   |
| West Nile virus (end of summer, autumn) | Serology, CSF capture IgM antibodies, PCR                                    | Fever, malaise, headache, myalgia, meningitis, encephalitis, pseudo-polyomyelitic syndrome, hyporeflexia   | Anti-WNV IG i.v. <sup>c</sup>   |

BKV: BK virus; CoV: coronavirus; i.v.: intravenous route; IF: immunofluorescence; anti-WNV IG i.v.: intravenous specific immunoglobulins against West Nile virus; IG i.v.: intravenous immunoglobulins; PML: progressive multifocal leukoencephalopathy; EM: electron microscopy; PCR: polymerase chain reaction; SARS: severe acute respiratory syndrome; CNS: central nervous system; PT: prothrombin time; p.o.: oral route; LCMV: lymphocytic choriomeningitis virus; HHV-6: type 6 human herpes virus; JCV: JC virus; HPV: human papillomavirus.

<sup>a</sup>Where possible, treatment should include a reduction in the intensity of immunosuppressor treatment.

<sup>b</sup>The PCR results are to be interpreted with caution when the possibility of latent infection exists.

<sup>c</sup>Therapies that might be used, though their efficacy has not been sufficiently established.

<sup>d</sup>May have a certain in vitro activity, though the in vivo usefulness is not known.

Neutropenia predominates in patients with acute leukemia, marrow aplasia or evolved myelodysplastic syndromes, and in patients subjected to intensive chemotherapy. In these situations the infections are predominantly caused by grampositive and gramnegative bacteria, fungi and viruses (herpes, RSV, influenza, parainfluenza).

Cellular immune deficiency in turn appears in patients with Hodgkin's lymphoma and other advanced lymphoproliferative syndromes, in treatments with glucocorticoids, purine analogs and treatments with monoclonal antibodies. In these situations it is common to find infections caused by intracellular bacteria, viruses (CMV, HSV, VZV, JCV, HHV-6, RSV), fungi and parasites.

Lastly, humoral immune deficiency predominates in patients with multiple myeloma, Waldenström's macroglobulinemia, chronic lymphatic leukemia (CLL) and splenectomized subjects. Infections are less frequent than in the previous groups and are fundamentally caused by encapsulated bacteria.

HPCT is a treatment option in hematological diseases, mainly in malignant blood disorders. Infection is an important complication, due to the summative immune depression caused by the background neoplastic disease itself, the conditioning regimen administered for transplantation, and the treatment of rejection and of graft-versus-host disease (GVHD). Other infection risk factors are the consideration of whether the donor is a relative or not, the patient viral serology condition prior to transplantation, and the time of development of the infection after transplantation.<sup>35</sup>

### Risk periods

There are three predictable immune deficiency risk periods in HPCT:

- Immediate post-transplant period: This starts with conditioning treatment and persists up to 30 days after transplantation. This period is characterized by intense neutropenia and lymphocytopenia. Regarding viral infections in this phase, the most common condition is the reactivation of HSV in previously seropositive patients.<sup>36</sup>
- Early post-grafting period: This starts with neutrophil recovery and persists up to day 100, when functional recovery of the B and T cells occurs. However, the presence of GVHD and its treatment may delay such immune recovery. CMV is the most important infectious agent in this phase. Other viral infections of note in this phase are those produced by RSV, influenza and parainfluenza virus, rhinoviruses, gastroenteritis due to rotavirus and Coxsackie virus, or reactivations of adenoviruses and HHV-6.
- Late post-grafting period: This extends from day 100 to the recovery of normal immunity, 18-36 months after HPCT, provided the patient is not subjected to immune suppression and remains free of GVHD. In this period there may be reactivation of VZV, and infection due to CMV (particularly in seropositive patients with chronic GVHD).<sup>37</sup>

### Principal agents

*Herpes simplex virus*: The most frequent clinical manifestation is gingivostomatitis, though in some cases the

disease can spread to the esophagus, larynx or skin of the perioral and perianal regions. It is sometimes difficult to distinguish between mucositis caused by HSV and that caused by the chemotherapy itself; as a result, empirical antiviral therapy is usually indicated. The reactivation of HSV can be reduced from 80% to less than 5% in seropositive recipients during the first month after transplant by prescribing aciclovir or valaciclovir from the time of conditioning and until recovery from mucositis<sup>35</sup> (see treatment and prophylaxis in Table 3).<sup>38,39</sup>

Varicella zoster virus: This manifests as a primary infection (5%) or as reactivation (95%) in 40% of the patients at some time during the first year after transplant, in patients with important cellular immune deficiency (Hodgkin's lymphoma), and in patients in which the condition was previously not common (CLL) and who had received treatment with new immunosuppressor drugs (fludarabine, rituximab, alemtuzumab). In addition to the typical cutaneous forms of presentation, hemorrhagic pneumonia, hepatitis, central nervous system involvement, thrombocytopenia and retinal necrosis may be observed. Occasionally in patients with HPCT, visceral involvement can occur without preceding skin lesions. GVHD is a potent predictor of dissemination. Mortality increases in the presence of lung involvement. The treatment is summarized in Table 3.<sup>38,39</sup>

Cytomegalovirus: CMV infection is an important complication in patients subjected to HPCT, for although the incidence of CMV disease has decreased in recent years thanks to the prevention strategies adopted, CMV seropositivity is considered an independent risk factor for GVHD and is associated with poorer survival, increased mortality due to bacteremia and fungal infections, and with transplant-related mortality.<sup>40</sup> The manifestations of CMV infection of the target organs are pneumonia, enterocolitis and (more rarely) retinitis. CMV pneumonia is the most frequent and serious manifestation, for even with treatment the mortality rate is 30-50%. This disorder is infrequent prior to graft consolidation, however. On the other hand, CMV pneumonia is being seen to behave as an emerging infection in adult leukemia patients treated with immunosuppressor drugs.<sup>41</sup> HPCT recipients can be classified into different CMV disease risk groups. High risk is assumed for allogenic transplants if there is T cell depletion of the precursor cell source, if the donor is not a relative, in the absence of identical histocompatibility antigen (HLA), the use of high-dose corticosteroids, treatment with alemtuzumab and purine analogs, and autologous transplants with CD34+ selection, treated with purine analogs and high-dose corticosteroids (Table 3). The diagnostic techniques of choice for early detection of the infection are antigenemia and PCR. In relation to the diagnosis, it is important to apply consensus-based criteria of infection and disease.<sup>42</sup> The regimens relating to prophylaxis, anticipatory treatment and guided treatment are explained in Table 3.

Community-acquired respiratory tract viruses: The most frequent in patients subjected to HPCT and in leukemia patients subjected to chemotherapy are paramyxoviruses (RSV, parainfluenza virus,<sup>1-3</sup> metapneumovirus), orthomyxoviruses (influenza A and B), rhinovirus, coronavirus NL63 and HKU1, adenoviruses and bocavirus, among others. Respiratory viral infections tend to manifest in relation to seasonal outbreaks and are acquired through contact with

Table 3 Prevention and treatment of viral infections in HPCT and other hematological processes

|     | Prevention  | Treatment   |
|-----|---|---|
| HSV | <p>HSV seronegative patients: no prophylaxis</p> <p>HSV seropositive patients subjected to allogeneic HPCT (also recommended in patients subjected to autologous HPCT in which severe mucositis is expected during conditioning)</p> <ul style="list-style-type: none"> <li>• Aciclovir i.v. 250 mg/m<sup>2</sup>/12 h or 5 mg/kg/12 h</li> <li>• If tolerated: oral aciclovir 400 mg/8-12 h</li> </ul> <p>Valaciclovir 500 mg/24 h</p>   | <p>Stomatitis:</p> <ul style="list-style-type: none"> <li>• Aciclovir i.v. 250 mg/m<sup>2</sup>/8 h or 5 mg/kg/8 h</li> </ul> <p>If tolerated:</p> <ul style="list-style-type: none"> <li>• Oral aciclovir 400 mg 5 times a day</li> <li>• Valaciclovir 500 mg/12 h</li> </ul> <p>In case of resistance to aciclovir:</p> <ul style="list-style-type: none"> <li>• Foscarnet i.v. 40 mg/kg/8 h</li> </ul> <p>Non-complicated, localized infection:</p> <ul style="list-style-type: none"> <li>• Oral aciclovir 800 mg 5 times a day</li> <li>• Valaciclovir 1000 mg/8 h</li> <li>• Famciclovir 500 mg/8 h</li> </ul> <p>Complicated, disseminated infection:</p> <ul style="list-style-type: none"> <li>• Aciclovir i.v. 500 mg/m<sup>2</sup>/8 h or 10 mg/kg/8 h</li> </ul> <p>Anticipatory or early treatment:</p> <p>Ganciclovir i.v., induction (I): 5 mg/kg/12 h; maintenance (M): 6 mg/kg/24 h</p> <p>Foscarnet i.v. I: 60 mg/kg x 2/24 h; M: 90 mg/kg/24 h</p> <p>Cidofovir i.v. I: 3 mg/kg once a week x 2 doses; M: 3-5 mg/kg every 2 weeks</p> <p>Valganciclovir p.o. I: 900 mg/12 h; M: 900 mg/24 h</p> <p>Treatment of disease:</p> <ul style="list-style-type: none"> <li>• Pneumonia: ganciclovir 5 mg/kg/12 h x 14-21 days, followed by 5 mg/kg/24 h x 3-4 weeks + immunoglobulins i.v.</li> <li>• Gastrointestinal infection: ganciclovir 5 mg/kg/12 h x 14-21 days followed by 5 mg/kg/24 h x 3-4 weeks</li> </ul> |
| VZV | <p>Vaccine: contraindicated, except in children with ALL in remission</p> <p>Chemoprophylaxis: consensus is lacking</p> <p>After risk exposure:</p> <ul style="list-style-type: none"> <li>• Specific gammaglobulin (under 96 h)</li> <li>• Alternative: aciclovir (started 7-9 days after exposure) 800 mg/6 h during 7 days</li> </ul>  |   |
| CMV | <p>Low risk:</p> <ul style="list-style-type: none"> <li>• Autologous/syngeneic: without specific measures</li> </ul> <p>Intermediate/high risk:</p> <ul style="list-style-type: none"> <li>• Allogeneic donor and CMV (-) recipient: CMV (-) or filtered hemotherapy</li> </ul> <p>Aciclovir i.v. 10 mg/kg/8 h; p.o. 800 mg 5 times a day (when tolerated)</p> <ul style="list-style-type: none"> <li>• Valaciclovir p.o. 1000 mg 4 times a day</li> <li>• Ganciclovir i.v. 5 mg/kg/12 h for 5 days, followed by 5 mg/kg/day</li> </ul> |   |

other infected individuals. If pneumonia develops, the associated mortality rate is high - particularly in the case of RSV and parainfluenza virus. There are no treatments of established efficacy for such infections, though inhalatory ribavirin is recommended in the case of RSV pneumonia, and neuraminidase inhibitors (oseltamivir, zanamivir) are advised in the case of influenza virus.<sup>43</sup> No effective chemoprophylactic measures are available for these infections in oncohematological patients; it is therefore essential to prevent these patients from becoming exposed to these virus, including nosocomial transmission.

**Adenoviruses:** Infection as a consequence of viral reactivation can occur in approximately 10% of all allogeneic HPCT recipients, and in a smaller proportion of autologous HPCT recipients. The most frequent manifestation is the hemorrhagic cystitis, though systemic pulmonary, hepatic, gastrointestinal and renal infection can also develop.<sup>44</sup> GVHD is an adenovirus infection risk factor following HPCT. There is no effective treatment for this infection.

**Other viruses:** Erythrovirus B19 in patients with chronic hemolytic anemia produces red-cell aplastic episodes. In HPCT patients it is an infrequent cause of anemia. The polyomaviruses (JC virus and BK virus) can give rise to progressive multifocal leukoencephalopathy (PML) and hemorrhagic cystitis, respectively. Most cases of EBV reactivation are subclinical and do not require treatment, though in other cases pleomorphic T lymphoma (PTL) of high mortality may result. HHV-6 in HPCT can give rise to situations of myelosuppression, skin rash, meningoencephalitis and GVHD exacerbation. HHV-8 in turn has been related to bone marrow hypoplasia, Kaposi's sarcoma, multicentric Castleman's disease, and cavity B cell lymphoma.

#### Viral infections and new immunosuppressor drugs

Treatment with fludarabine (a purine analog) and alemtuzumab (anti-CD52 IgG1 kappa humanized monoclonal



antibody) is associated with an increased frequency of infections due to HSV and VZV, and to infection and disease caused by CMV.<sup>45</sup>

Rituximab (a chimeral monoclonal antibody targeted to the CD20 receptor) has been associated with the development of pure red-cell aplasia due to enterovirus B19, fulminant hepatitis due to HBV, the reactivation of latent HBV infection, cases of fatal disseminated varicella infection, CMV pneumonia and infections due to HSV and VZV. Its peri-implant administration in autologous HPCT has been associated to unusual infections such as PML, retinitis and CMV pneumonitis.<sup>46</sup>

## References

- Linden PK. Approach to the immunocompromised host with infection in the intensive care unit. *Infect Dis Clin North Am.* 2009;23:535-56.
- Razonable RR, Eid AJ. Viral infections in transplant recipients. *Minerva Med.* 2009;100:479-501.
- Castón JJ, Cisneros JM, Torre-Cisneros J. Effects of viral infection on transplant recipients. *Enferm Infecc Microbiol Clin.* 2007;25:535-48.
- Pérez-Sola MJ, Castón JJ, Solana R, Rivero A, Torre-Cisneros J. [Indirect effects of cytomegalovirus infection in solid organ transplant recipients]. *Enferm Infecc Microbiol Clin.* 2008;26:38-47.
- San Juan R, Aguado JM, Lumbreras C, Fortun J, Muñoz P, Gavalda J, et al. RESITRA Network of the Spanish Study Group of Infection in Transplantation. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. *Clin Infect Dis.* 2008;47:875-82.
- Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, et al. Cytomegalovirus in transplantation –challenging the status quo. *Clin Transplant.* 2007;21:149-58.
- Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. *Autoimmun Rev.* 2007;7:96-101.
- Smith JM, McDonald RA. Emerging viral infections in transplantation. *Pediatr Transplant.* 2006;10:838-43.
- Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. *Transplantation.* 2008;86:1327-39.
- Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. *Clin Infect Dis.* 2009;48:772-86.
- Blanes M, Gómez D, Giménez MJ, Salavert M. Evaluación de la infección en el donante y en el receptor de trasplante de órgano sólido y de progenitores hematopoyéticos. Capítulo 8. In: Aguado JM, editor. *Infecciones en pacientes trasplantados.* 3rd ed. Madrid: Elsevier España; 2009. p. 131-58.
- Opelz G, Daniel V, Naujokat C, Döhler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. *Transplantation.* 2009;88:962-7.
- Slifkin M, Doron S, Snyderman DR. Viral prophylaxis in organ transplant patients. *Drugs.* 2004;64:2763-92.
- Benmarzouk-Hidalgo OJ, Cordero E, Martín-Peña A, García-Prado E, Gentil MA, Gomez-Bravo MA, et al. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. *Antivir Ther.* 2009;14:641-7.
- San Juan R, Yebra M, Lumbreras C, López-Medrano F, Lizasoain M, Meneu JC, et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. *Clin Transplant.* 2009;23:666-71.
- Fishman JA. Infection in solid-organ transplant recipients. *N Engl J Med.* 2007;357:2601-14.
- Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. *Transpl Infect Dis.* 2009;11:195-202.
- Ljungman P, Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. *J Clin Virol.* 2006;37(Suppl 1):S87-91.
- Len O, Gavalda J, Aguado JM, Borrell N, Cervera C, Cisneros JM, et al. RESITRA. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. *Clin Infect Dis.* 2008;46:20-7.
- Hidalgo M, Lumbreras C, Aguado JM. [Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants]. *Med Clin (Barc).* 1996;107:310-6.
- Heslop HE. How I treat EBV lymphoproliferation. *Blood.* 2009;114:4002-8.
- Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. *Transplantation.* 2009;87:621-30.
- Hirsch HH. BK virus: opportunity makes a pathogen. *Clin Infect Dis.* 2005;41:354-60.
- Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. *Clin Infect Dis.* 2006;43:40-8.
- Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. *Am J Transplant.* 2009;9:1707-13.
- Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. *Liver Transpl.* 2009;15:738-46.
- Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. *J Hepatol.* 2008;49:274-87.
- Berenguer M. Recurrent allograft disease: viral hepatitis. *Acta Gastroenterol Belg.* 2005;68:337-46.
- Miró JM, Torre-Cisneros J, Moreno A, Tuset M, Quereda C, Laguno M, et al. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. *Enferm Infecc Microbiol Clin.* 2005;23:353-62.
- Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. *World J Gastroenterol.* 2009;15:3713-24.
- Miró JM, Agüero F, Laguno M, Tuset M, Cervera C, Moreno A, et al. Hospital Clinic OLT in HIV Working Group. Liver transplantation in HIV/hepatitis co-infection. *J HIV Ther.* 2007;12:24-35.
- Torre-Cisneros J, Fortún J, Aguado JM, De la Cámara R, Cisneros JM, Gavalda J, et al. [Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients]. *Enferm Infecc Microbiol Clin.* 2005;23:424-37.
- Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. *Clin Infect Dis.* 2008;47:702-11.
- Mateos MC, Arguiñano JM, Ardaiz MA, Oyarzábal FJ. [Infections in non-transplanted oncohaematological patients]. *An Sist Sanit Navar.* 2005;28:59-81.
- Van Burik J-A, Weisdorf D. Infecciones en los receptores de trasplante de células madre hematopoyéticas. In: Mandell GL, Bennett JE, Dolin R, editors. *Enfermedades infecciosas. Principios y práctica.* 6th ed. Madrid: Elsevier España; 2006. p. 3486-501.
- Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Clin Infect Dis.* 2001;2:139-44.

37. Boeckh M, Leiserin W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. *Blood*. 2003;101:407-14.
38. De la Cámara R. [Viral infections in hematologic patients: prevention, diagnosis and treatment]. *Haematologica* (ed. esp.). 2002;87(Suppl 1):221-6.
39. Jancel T, Penzak SR. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. *Semin Hematol*. 2009;46:230-47.
40. Broers AE, Van Der Holt R, Van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. *Blood*. 2000;95:2240-5.
41. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. *Clin Infect Dis*. 2001;32:539-45.
42. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. *Clin Infect Dis*. 2002;34:1094-7.
43. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. *Br J Haematol*. 2008;143:455-67.
44. Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, Rocha V, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. *Haematologica*. 2007;92:1254-7.
45. Williams T, Roach J, Rugg T, Brettman L. Frequency of cytomegalovirus pneumonia following Alemtuzumab. Treatment in lymphoid malignancies: Review of 1,538 patients. *Blood*. 2001;98(294b; abstract):4923.
46. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem rescue and peritransplantation rituximab. *Blood*. 2002;99:1486-8.